B+
Bull case
25%
Probability
Target price
$46.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
CLDX
Celldex TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that the April financing removed a near-term capital constraint, while barzolvolimab keeps generating development momentum across multiple inflammatory indications and Phase 3 CSU enrollment finished ahead of guidance, preserving a potentially important 2026-2027 registration path [#8-K-2026-04-02] [#8-K-2026-02-25].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.4.
What can break
Biotech execution risk remains elevated around enrollment quality, data reproducibility across indications, regulatory interpretation, and eventual commercialization readiness for barzolvolimab.
Momentum
65
Value
41
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $34.00 · Bull $46.00 · Bear $24.00Analysis 2026-05-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $58.79
Why
Momentum65 · Δ7d +4.2
Value41 · Δ7d 0.0
Sentiment48 · Δ7d +5.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.4.
Contradictions & invalidation
- • Biotech execution risk remains elevated around enrollment quality, data reproducibility across indications, regulatory interpretation, and eventual commercialization readiness for barzolvolimab.
- • CLDX is still highly dependent on a small number of 2026 clinical readouts, so timing slips or ambiguous efficacy/safety outcomes could pressure the stock disproportionately.
- • The bear case is that CLDX remains a low-coverage, binary biotech where the investment case is concentrated in a narrow set of readouts; negative or merely mixed data in PN, AD, or late-2026 CSU could erase much of the current platform premium, and the April raise can also be read as a reminder that cash needs remain material ahead of commercialization.
Catalyst clock
2026-06-15
Post-offering cash reset and dilution overhang digestion
Lead driver: Sentiment · See AI snapshot
Momentum
65
9% active weight
Current posture
7d trendImproving
Δ7d
+4.2
Δ21d
-23.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
48
62% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+9.2
Why this grade
Composite grade D. Momentum 64.7 / Value 41.2 / Sentiment 48.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-03. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-05-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.29B
Beta
1.25
Shares Out
78.53M
P/E (TTM) · Derived
-10.8
P/S (TTM)
654.27
P/FCF (TTM) · Derived
-11.95
Rev YoY
-97.0%
EPS YoY
+10.8%
Gross Margin
-2049.4%
Op Margin
-9855.4%
Net Debt
-$511.84M
Current Ratio
11.82
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data